- Home
- Automated
- List of product information
- ALBUNORM SOLUTION FOR INFUSION 20% [SIN15160P]
ALBUNORM SOLUTION FOR INFUSION 20% [SIN15160P]
Active ingredients: ALBUNORM SOLUTION FOR INFUSION 20%
On this page
Product Info
ALBUNORM SOLUTION FOR INFUSION 20%
[SIN15160P]
Product information
Active Ingredient and Strength | HUMAN ALBUMIN - 200 G/1,000 ML |
Dosage Form | INFUSION, SOLUTION |
Manufacturer and Country | OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M.B.H - AUSTRIA |
Registration Number | SIN15160P |
Licence Holder | WELLCHEM PHARMACEUTICALS PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | B05AA01 |
4.1 Therapeutic indications
Restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated, and use of a colloid is appropriate.
The choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient, based on official recommendations.
4.2 Posology and method of administration
The concentration of the albumin preparation, dosage and the infusion-rate should be adjusted to the patient’s individual requirements.
Posology
The dose required depends on the size of the patient, the severity of trauma or illness and on continuing fluid and protein losses. Measures of adequacy of circulating volume and not plasma albumin levels should be used to determine the dose required.
If human albumin is to be administered, haemodynamic performance should be monitored regularly; this may include:
arterial blood pressure and pulse rate
central venous pressure
pulmonary artery wedge pressure
urine output
electrolyte
haematocrit/haemoglobin
Paediatric population
Data on the use of Albunorm 20% in children are limited; therefore, the product should only be administered to these individuals if the benefits clearly outweigh potential risks.
Method of administration
Human albumin can be directly administered by the intravenous route, or it can also be diluted in an isotonic solution (e.g. 5% glucose or 0.9% sodium chloride).
The infusion rate should be adjusted according to the individual circumstances and the indication.
In plasma exchange the infusion-rate should be adjusted to the rate of removal.
4.3 Contraindications
Hypersensitivity to albumin preparations or to any of the excipients.
